Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present
results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual
Meeting in Orlando, on May 29, 2009. The study was carried out at MD
Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center.
Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the
presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP
competitive substrate-pocket directed SRC inhibitor, in patients with advanced
malignancies."

The presentation will provide data from this multi-center Phase 1 trial that
utilized the standard 3+3 design to determine the Maximum Tolerated Dose
(MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with
refractory solid tumors. Patients who responded to treatment will be
highlighted.

This presentation was designated as Best of ASCO(R) which features
high-impact abstracts from the 2009 ASCO Annual Meeting that represent the
most relevant, cutting-edge science in oncology today. This information has
been selected to be presented at meetings in the US and internationally
because it highlights the latest scientific findings in primary disease sites
and practice-changing advances in cancer prevention and treatment.

Kinex Pharmaceuticals is a drug discovery and development company that is
focused on next generation drugs to treat cancer and immuno-inflammatory
diseases. The Company has utilized its platform technologies to identify
highly selective inhibitors of therapeutically relevant targets that are
involved in signal transduction and cell cycle control.

CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex
Pharmaceuticals, +1-716-881-8984

SOURCE Kinex Pharmaceuticals

Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals,
+1-716-881-8984